Docoh
Loading...

GDRX GoodRx

News

From Benzinga Pro
Jim Cramer Shares His Thoughts On AT&T, GoodRx And More
24 Jan 22
Long Ideas, News, Small Cap, Top Stories, Media, Trading Ideas
On CNBC’s "Mad Money Lightning Round," Jim Cramer said he doesn’t hate AT&T Inc. (NYSE: T) anymore.
Ominous Death Cross Forms On GoodRx Holdings's Chart
11 Jan 22
Markets, Movers, Trading Ideas
If history is any guide, there may be trouble ahead for shares of GoodRx Holdings (NASDAQ:GDRX). A so-called "death cross" has formed on its chart and, not surprisingly, this could be bearish for the stock.
Benzinga's Top Ratings Upgrades, Downgrades For January 7, 2022
7 Jan 22
Upgrades, Downgrades, Initiation, Intraday Update, Analyst Ratings
Analyst Ratings For GoodRx Holdings
7 Jan 22
Analyst Ratings
Analysts have provided the following ratings for GoodRx Holdings (NASDAQ:GDRX) within the last quarter:
Goldman Sachs Initiates Coverage On GoodRx Holdings with Buy Rating, Announces Price Target of $43
7 Jan 22
News, Price Target, Initiation, Analyst Ratings
Goldman Sachs analyst Eric Sheridan initiates coverage on GoodRx Holdings (NASDAQ:GDRX) with a Buy rating and announces Price Target of $43.
Analyst Ratings For GoodRx Holdings
21 Dec 21
Analyst Ratings
Within the last quarter, GoodRx Holdings (NASDAQ:GDRX) has observed the following analyst ratings:
Benzinga's Top Ratings Upgrades, Downgrades For December 21, 2021
21 Dec 21
Upgrades, Downgrades, Initiation, Intraday Update, Analyst Ratings
Stephens & Co. Initiates Coverage On GoodRx Holdings with Overweight Rating, Announces Price Target of $45
21 Dec 21
News, Price Target, Initiation, Analyst Ratings
Stephens & Co. initiates coverage on GoodRx Holdings (NASDAQ:GDRX) with a Overweight rating and announces Price Target of $45.
Morgan Stanley Maintains Equal-Weight on GoodRx Holdings, Raises Price Target to $41
17 Dec 21
News, Price Target, Analyst Ratings
Morgan Stanley maintains GoodRx Holdings (NASDAQ:GDRX) with a Equal-Weight and raises the price target from $38 to $41.
Veru's Benign Prostatic Hyperplasia Treatment Wins FDA Approval
13 Dec 21
Biotech, Long Ideas, News, Health Care, Small Cap, FDA, Movers, Trading Ideas, General
The
Benzinga's Top Ratings Upgrades, Downgrades For December 2, 2021
2 Dec 21
Upgrades, Downgrades, Initiation, Intraday Update, Analyst Ratings
Jefferies Initiates Coverage On GoodRx Holdings with Buy Rating, Announces Price Target of $47
2 Dec 21
News, Price Target, Initiation, Analyst Ratings
Jefferies analyst Glen Santangelo initiates coverage on GoodRx Holdings (NASDAQ:GDRX) with a Buy rating and announces Price Target of $47.
Expert Ratings For GoodRx Holdings
11 Nov 21
Analyst Ratings
GoodRx Holdings (NASDAQ:GDRX) has observed the following analyst ratings within the last quarter:
Barclays Maintains Overweight on GoodRx Holdings, Raises Price Target to $47
11 Nov 21
News, Price Target, Analyst Ratings
Barclays analyst Steve Valiquette maintains GoodRx Holdings (NASDAQ:GDRX) with a Overweight and raises the price target from $45 to $47.
SVB Leerink Maintains Outperform on GoodRx Holdings, Lowers Price Target to $49
11 Nov 21
News, Price Target, Analyst Ratings
SVB Leerink analyst Stephanie Davis maintains GoodRx Holdings (NASDAQ:GDRX) with a Outperform and lowers the price target from $56 to $49.
GoodRx Holdings: Q3 Earnings Insights
10 Nov 21
Earnings
GoodRx Holdings (NASDAQ:GDRX) reported its Q3 earnings results on Wednesday, November 10, 2021 at 04:07 PM. Here's what investors need to know about the announcement.
GoodRx Holdings Q3 EPS $0.09, Inline, Sales $195.10M Beat $194.89M Estimate
10 Nov 21
Earnings, News
GoodRx Holdings (NASDAQ:GDRX) reported quarterly earnings of $0.09 per share which met the analyst consensus estimate. This is unchanged from the same period last year. The company reported quarterly sales of $195.10
Earnings Scheduled For November 10, 2021
10 Nov 21
Earnings, News, Pre-Market Outlook, Markets
Companies Reporting Before The Bell • LumiraDx (NASDAQ:LMDX) is projected to report quarterly loss at $0.24 per share on revenue of $94.32 million.